Zocitab: Advanced Relief for Major Depressive Disorder
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $17.29 | $172.86 (0%) | 🛒 Add to cart |
| 20 | $14.92 | $345.72 $298.42 (14%) | 🛒 Add to cart |
| 30 | $14.16 | $518.58 $424.84 (18%) | 🛒 Add to cart |
| 40 | $13.78 | $691.44 $551.26 (20%) | 🛒 Add to cart |
| 50 | $13.55
Best per pill | $864.30 $677.68 (22%) | 🛒 Add to cart |
Synonyms | |||
Zocitab is a prescription medication containing sertraline hydrochloride, a selective serotonin reuptake inhibitor (SSRI) specifically formulated for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action involves the potent inhibition of serotonin reuptake in the central nervous system, leading to increased synaptic concentrations of this key neurotransmitter. This pharmacological profile is clinically proven to alleviate the core symptoms of depression, including persistent low mood, anhedonia, and significant functional impairment. Zocitab represents a cornerstone in modern psychopharmacology, offering a well-tolerated and effective option for long-term management.
Features
- Active Ingredient: Sertraline Hydrochloride
- Available Strengths: 25 mg, 50 mg, and 100 mg film-coated tablets
- Pharmacological Class: Selective Serotonin Reuptake Inhibitor (SSRI)
- Bioavailability: Demonstrates consistent linear pharmacokinetics
- Half-life: Approximately 26 hours, supporting once-daily dosing
- Excretion: Primarily hepatic metabolism via CYP450 enzymes, with renal elimination of metabolites
Benefits
- Achieves significant improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo.
- Reduces the frequency and intensity of depressive episodes, supporting sustained remission.
- Improves overall quality of life, social functioning, and daily activity engagement.
- Features a favorable side effect profile relative to older antidepressant classes like tricyclics.
- Supports long-term maintenance therapy to prevent relapse and recurrence.
- May alleviate comorbid anxiety symptoms often associated with major depressive disorder.
Common use
Zocitab is primarily indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adult patients. It is also approved for the management of obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD). Treatment should be initiated under the supervision of a qualified healthcare professional following a comprehensive psychiatric assessment and diagnosis. The therapeutic response is typically observed within 2 to 4 weeks, though full efficacy may require several weeks of consistent dosing.
Dosage and direction
The recommended starting dosage for Zocitab in adults with major depressive disorder is 50 mg administered orally once daily, either in the morning or evening, with or without food. Dosage may be adjusted at intervals of no less than one week, based on therapeutic response and tolerability, up to a maximum daily dose of 200 mg. For panic disorder, PTSD, and social anxiety disorder, the initial dose is 25 mg once daily, with an increase to 50 mg after one week. In patients with hepatic impairment, a lower initial dose or prolonged adjustment intervals are advised. Tablets should be swallowed whole and not chewed or crushed.
Precautions
Patients should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial few months of therapy or following dosage changes. Zocitab may cause activation of mania/hypomania in patients with bipolar disorder; screen for bipolar disorder prior to initiation. Use with caution in patients with a history of seizures. SSRI treatment can lead to hyponatremia, especially in elderly patients or those taking diuretics. Discontinuation symptoms may occur upon abrupt cessation; taper dose gradually under medical supervision. Inform your physician of any planned surgical procedures.
Contraindications
Zocitab is contraindicated in patients with known hypersensitivity to sertraline or any component of the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome. Zocitab must not be initiated within 14 days of discontinuing an MAOI, and at least 14 days should elapse after stopping Zocitab before starting an MAOI. It is also contraindicated with pimozide due to the potential for QT prolongation.
Possible side effect
Common adverse reactions (≥5% and greater than placebo) include nausea, diarrhea/loose stools, insomnia, somnolence, dry mouth, increased sweating, dizziness, fatigue, tremor, indigestion, and decreased appetite. Sexual side effects, such as decreased libido, delayed ejaculation, or anorgasmia, may occur. Less frequently, rash, palpitations, visual disturbances, and weight changes have been reported. Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Zocitab is a moderate inhibitor of CYP2D6 and may increase plasma concentrations of drugs metabolized by this enzyme (e.g., tricyclic antidepressants, antipsychotics like haloperidol, certain beta-blockers). Concomitant use with other serotonergic drugs (e.g., triptans, tramadol, other SSRIs/SNRIs) increases the risk of serotonin syndrome. Use with warfarin may require closer monitoring of prothrombin time. Drugs that interfere with serotonin reuptake (e.g., linezolid, intravenous methylene blue) are contraindicated. Avoid use with NSAIDs or aspirin due to potential increased bleeding risk.
Missed dose
If a dose of Zocitab is missed, it should be taken as soon as remembered on the same day. If it is near the time of the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining a consistent daily routine is important for stable serum concentrations and optimal therapeutic effect.
Overdose
Symptoms of Zocitab overdose may include serotonin syndrome (agitation, confusion, tachycardia, hyperthermia, rigidity, myoclonus), somnolence, nausea, vomiting, tachycardia, dizziness, and agitation. There is no specific antidote for sertraline overdose. Management involves supportive care and symptomatic treatment. Gastric lavage may be considered if presented early. Activated charcoal can be administered. Ensure adequate airway, oxygenation, and ventilation. Monitor cardiac function and vital signs continuously.
Storage
Store Zocitab tablets at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the bottle tightly closed and protect from light and moisture. Dispense in the original container with the dessicant provided. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card.
Reviews
“After six weeks on Zocitab 50 mg, my MADRS score decreased from 32 to 11. Patient reports significant improvement in energy and mood stability with minimal side effects beyond initial mild nausea.” – Dr. Elena Rostova, Psychiatrist
“Zocitab has been a reliable first-line SSRI in my practice for over a decade. Its predictable pharmacokinetics and generally favorable tolerability make it suitable for long-term management of moderate to severe MDD.” – Prof. Michael Thorne, Clinical Pharmacology
“Notable improvement in sleep architecture and reduction in early morning awakening in patients treated with Zocitab for MDD with comorbid insomnia. Dosage adjustment was straightforward.” – Dr. Susan Li, Sleep Specialist